Prograf approved for combination therapy with mycophenolate mofetil (MMF) in kidney transplant recipients - MPR
Links shared publicly online about this topic.
- 2,010total visits
Prograf approved for combination therapy with mycophenolate mofetil (MMF) in kidney transplant recipients - MPR
empr.com —
The FDA has approved Prograf (tacrolimus, from Astellas) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients.
View full resource at empr.com
Tags: Urinary System, Organ Transplantation, Organ Transplant Rejection Medication, Kidney Transplant, FDA, Prograf, CellCept, Transplantation
Most Recently Shared on May 28, 2009 at 8:20 pm By:
MPR News: Prograf approved for combination therapy with mycophenolate mofetil (MMF) in kidney transplan.. http://tinyurl.com/mpaqr6
Advertisement
